•   
  •   
  •   

Health & Fit AstraZeneca COVID Vaccine Set for New Trials After Scientists Raise Doubts Over Initial Data

21:45  26 november  2020
21:45  26 november  2020 Source:   newsweek.com

Internal AstraZeneca safety report sheds light on neurological condition suffered by vaccine trial participant

  Internal AstraZeneca safety report sheds light on neurological condition suffered by vaccine trial participant CNN has obtained an internal safety report by pharmaceutical giant AstraZeneca that sheds light on the neurological condition suffered by one of the participants in its coronavirus vaccine clinical trial. © Jason Alden/Bloomberg/Getty Images A sign featuring the AstraZeneca Plc logo stands at the company's DaVinci building at the Melbourn Science Park in Cambridge, U.K., on Monday, June 8, 2020. AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal on record.

The Covid -19 vaccine being developed by Oxford University and AstraZeneca will be tested again, the drug maker's CEO said on Thursday, following growing doubts over A new trial , Soriot said, would probably not delay the vaccine 's authorization by British and EU regulators, although it could prove a

Those vaccines use a new gene-based technology that, despite its impressive clinical results thus far, requires the shots to be In the days since the results were announced, independent scientists and U.S. government officials said the data is further proof that vaccines can prevent Covid -19, but they

Drug maker AstraZeneca is expected to begin further trials of its potential COVID-19 vaccine, after scientists raised doubts about data about its effectiveness.

a close up of a bottle: An illustration picture shows vials with COVID-19 Vaccine stickers attached and syringes with the logo of British pharmaceutical company AstraZeneca on November 17, 2020. © JUSTIN TALLIS/AFP via Getty Images An illustration picture shows vials with COVID-19 Vaccine stickers attached and syringes with the logo of British pharmaceutical company AstraZeneca on November 17, 2020.

The British-Swedish company, which developed the vaccine with the University of Oxford in the U.K., became the third company in a week to reveal it may have found a vaccine that was highly effective at preventing symptoms.

However, scientists had raised concerns about the vaccine's levels of effectiveness after it emerged the interim data had been taken from two separate sub-trials—in the U.K. and Brazil—which brought varying degrees of success.

Why it’s still unlikely we’ll have a Covid-19 vaccine before Election Day

  Why it’s still unlikely we’ll have a Covid-19 vaccine before Election Day Trump wants a vaccine before November, but his top advisors say that’s near impossible.“The week before last, the head of the Centers for Disease Control Dr. Redfield said it would be summer before the vaccine would become generally available to the public. You said that he was confused and mistaken,” Wallace said.

The clinical trial for AstraZeneca 's coronavirus vaccine has already resumed in other countries AstraZeneca told CNN that "to maintain trial integrity and protect the privacy right of patients The scientists , however, say the company and the university have not been consistent in how they apply

AstraZeneca Pauses Covid -19 Vaccine Trial . AstraZeneca Plc stopped giving shots of its experimental coronavirus vaccine after a person The setback comes as a group of international scientists raised questions over a fast-moving vaccine from Russia, saying some results of a study

One, in which participants received two full doses a month apart, showed the vaccine was 62 percent effective. The other, in which people were given a half dose followed by a full dose, showed the vaccine was 90 percent effective.

It later emerged that the seemingly more successful method, had only been tested after a contractor accidentally administered half doses to volunteers, and that it had not been tested on those older than 55, who are most at risk to COVID-19.

"Now that we've found what looks like a better efficacy we have to validate this, so we need to do an additional study," the company's CEO, Pascal Soriot, said on Thursday, in his first interview since the initial data were released.

AstraZeneca and Oxford Say Vaccine Is Up to 90 Percent Effective

  AstraZeneca and Oxford Say Vaccine Is Up to 90 Percent Effective AstraZeneca and the University of Oxford announced on Monday that their inexpensive, easy-to-produce coronavirus vaccine appears effective, the latest in a string of encouraging results this month from leading vaccine developers. An early analysis of data from late-stage clinical trials found that AstraZeneca’s vaccine was either 62 percent or 90 percent effective, depending on the manner in which the doses were given. While the overall efficacyAn early analysis of data from late-stage clinical trials found that AstraZeneca’s vaccine was either 62 percent or 90 percent effective, depending on the manner in which the doses were given.

AstraZeneca says late-stage trials of its COVID -19 vaccine were “highly effective’’ in preventing disease. A vaccine developed by AstraZeneca and the University of Oxford prevented 70% of people from developing the coronavirus in late-stage trials , the team reported Monday Nov.

Trials will determine how well the vaccine will protect from the COVID -19 disease and measure In addition, emerging data suggest that a T-cell response could play an important role in mitigation of the disease. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative

It is likely to be another "international study, but this one could be faster because we know the efficacy is high so we need a smaller number of patients," he added.

Last week, U.S. manufacturers Pfizer and Moderna also released data showing that each of their vaccines offered 95 percent protection. That figure came from single Phase 3 clinical trials, each of which involved about 30,000 people.

This is a developing story and will be updated.

Related Articles

  • How Do the AstraZeneca, Moderna and Pfizer Coronavirus Vaccines Differ? What We Know About Each
  • Why Oxford-AstraZeneca COVID Vaccine Could Be More Important Than Pfizer and Moderna's in Ending Pandemic
  • Virus Expert Says COVID Will 'Not Go Away' and Could Be Around for 'Rest of Our Lives'

Start your unlimited Newsweek trial

FDA advisory committee to consider second COVID-19 vaccine, this one from Moderna, during all-day meeting .
An FDA advisory panel is expected Thursday to recommend authorization of the COVID-19 vaccine developed by Moderna. It could be in states by Monday.This time, the committee is reviewing a vaccine made by Cambridge, Massachusetts, biotech Moderna, with similar technology and results as the one it supported last week by Pfizer and its German collaborator, BioNTech.

usr: 0
This is interesting!